Full-Time
Updated on 9/4/2026
Biotech immunology company developing therapeutic antibodies
$204k - $280.5k/yr
Remote in USA
Remote
Must live within the Wisconsin, Illinois, or Michigan market; relocation benefits are not provided. Extensive travel of up to 80% is required.
Bachelor's
See people who can refer or advise you
argenx develops antibody therapies to treat autoimmune diseases and cancer by translating scientific discoveries in immunology into therapeutic antibodies. Its work centers on R&D and then licensing and collaborations for commercialization, with cusatuzumab being developed with Janssen R&D to target hematological cancers such as leukemia. The company funds and accelerates discovery mainly through partnerships and licenses, bringing products to market via partner-based commercialization rather than building its own sales force. Its goal is to advance antibody-based treatments for serious autoimmune diseases and cancer by turning scientific insights into clinically useful therapies through industry and academic collaborations.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Ghent, Belgium
Founded
2008
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
BenchSci announces two-year enterprise agreement with argenx to advance ai-driven preclinical drug discovery. Scientist-led competitive selection deepens BenchSci's presence in European biopharma TORONTO - BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation...
Argenx has achieved 18 consecutive quarters of revenue growth, with second-quarter 2026 sales rising 60% year-over-year and 17% sequentially. The biotech's Vyvgart and Vyvgart Hytrulo therapies continue gaining traction in treating severe autoimmune diseases. Earnings reached $472 million in Q2, nearly double the prior year, with expanding operating margins. The company holds approvals in generalised myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. Argenx recently reported positive late-stage results for Vyvgart Hytrulo in autoimmune myositis, affecting around 100,000 Americans. Management sees this as a multibillion-dollar opportunity. The company expects Phase 3 results for empasiprubart in multifocal motor neuropathy during Q4 2026. CFO Karl Gubitz noted only 20% of gMG patients currently receive novel biologics, suggesting significant growth potential.
Not Moderna: this biotech stock still has potential after an 11,000% rally! Since its IPO in 2014, the Argenx stock has risen by more than 11,150 percent. A study success is fueling new enthusiasm for Argenx. The background. Photo: Andrew Brookes - Westend61 Europe's largest listed pure-play biotech group currently knows only one direction: upwards. The Argenx stock has gained 21 percent since last Friday's closing price, marked a record high and is heading for its best week in more than three years. This puts it at the top of the winners in the Stoxx Europe 600, reports Bloomberg. The long-term record is even more spectacular: Since the Brussels listing in July 2014, the price has shot up by more than 11,150 percent. The market capitalization climbed to 55.4 billion euros - putting Argenx ahead of Moderna again. Trade your assessment of BioNTech SE ADR!
argenx reported positive Phase 3 results for its ALKIVIA trial evaluating VYVGART Hytrulo in adults with autoimmune myositis. The trial met its primary endpoint, with patients showing statistically significant improvements in Total Improvement Score over 52 weeks versus placebo. The study marks the first Phase 3 trial demonstrating benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies. The safety profile remained consistent with prior studies. The company recently received US FDA priority review for VYVGART in seronegative generalized myasthenia gravis, with a decision expected on 10 May 2026. These label expansions could broaden VYVGART's reach across multiple autoimmune conditions. argenx's shares rose 11.5% following the announcement. The company's narrative projects $9.7 billion revenue and $3.5 billion earnings by 2029, requiring 22.3% yearly revenue growth.
argenx, a commercial-stage biopharma company specialising in autoimmune disease treatments, has attracted investor attention following recent share price movements. The stock closed at €767, up approximately 6% over the past week and 38.6% over the past year, bringing its market value to around €47.97 billion. The company generates revenue of €5.3 billion, primarily from its VYVGART franchise, with operations spanning the United States, Japan, China, and other markets. According to a widely followed valuation narrative, argenx appears 11.7% overvalued, with a fair value estimate of €686.43. The analysis credits the company's leadership in FcRn inhibitors and strong commercial growth, whilst noting typical biotech risks including single-asset dependence and pricing pressure. Revenue has doubled over two years, supporting the growth thesis.